Back to Results

Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd. is a NASDAQ-listed common stock of a clinical-stage biotechnology company based in Ness Ziona, Israel. Through its subsidiaries, the company focuses on macrophage reprogramming immunotherapy and is developing AllocetraTM, a cell therapy intended to help restore macrophage homeostasis. Its pipeline includes an intra-articular AllocetraTM program for knee osteoarthritis, which is in a phase 1/2 trial, an intra-articular osteoarthritis program for the temporomandibular joint (TMJ), and Allocetra-OTS for adult sepsis patients with organ failure, which is in phase 2. The company was founded in 2005 and changed its name from Enlivex Therapeutics Ltd. to Enlivex Ltd. in February 2026.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-ENLV
$5.26
11.5% Upside
Fair
$300 6,255.9% Upside
—
Bargain
Good
—
—
—
0.0%
August 24, 2026
0.1x
0.0x
—
74.564 M
67.201 M
0.9%
24.3%
14.8
—
-0.8%
Send a message
Valuation • Fair Value

Enlivex Therapeutics Ltd (NASDAQ-ENLV) Fair Value by Valuation Model

Compare the primary fair value estimate for Enlivex Therapeutics Ltd (NASDAQ-ENLV) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$5.26

Estimated upside of 11.5% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$853.08

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$5.26

Comparable-company valuation reference.

Analyst Price Target

$300 6,255.9% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use this section to compare the primary fair value estimate for Enlivex Therapeutics Ltd (NASDAQ-ENLV) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Enlivex Therapeutics Ltd (NASDAQ-ENLV)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-14.668 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Enlivex Therapeutics Ltd (NASDAQ-ENLV) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Enlivex Therapeutics Ltd (NASDAQ-ENLV)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

14.8

Relatively strong balance-sheet zone.

FCF / Net Income

-0.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Enlivex Therapeutics Ltd (NASDAQ-ENLV). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Enlivex Therapeutics Ltd (NASDAQ-ENLV)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 24, 2026

Days to Earnings

34

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Enlivex Therapeutics Ltd (NASDAQ-ENLV), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Enlivex Therapeutics Ltd (NASDAQ-ENLV) Stock Forecast & Technical Outlook

Review Enlivex Therapeutics Ltd (NASDAQ-ENLV) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Enlivex Therapeutics Ltd (NASDAQ-ENLV)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Enlivex Therapeutics Ltd (NASDAQ-ENLV) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Enlivex Therapeutics Ltd (NASDAQ-ENLV) Stock FAQ

Quick answers about Enlivex Therapeutics Ltd (NASDAQ-ENLV) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$5.26
Estimated upside 11.5%
Valuation Rating
Undervalued
Estimated upside of 11.5%
Analyst Target
$300 6,255.9% Upside
Data is currently unavailable
Financial Health
Good
Current financial-health read

The current fair value estimate for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is $5.26. This implies an estimated upside of 11.5% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 11.5% versus the current market price.

The available analyst price target for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is $300 6,255.9% Upside.

The current financial health read for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is August 24, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Enlivex Therapeutics Ltd (NASDAQ-ENLV) is 0.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Enlivex Therapeutics Ltd is 74.564 M.

The current enterprise value listed for Enlivex Therapeutics Ltd is 67.201 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Enlivex Therapeutics Ltd is NASDAQ-ENLV, and the stock is listed on NASDAQ.

Enlivex Therapeutics Ltd (NASDAQ-ENLV) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Enlivex Therapeutics Ltd is 0.9%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Enlivex Therapeutics Ltd is 24.3%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on NASDAQ View more

Amgen Inc (AMGN) Amgen Inc (AMGN)
Gilead Sciences Inc (GILD) Gilead Sciences Inc (GILD)
Vertex Pharmaceuticals Inc (VRTX) Vertex Pharmaceuticals Inc (VRTX)
Regeneron Pharmaceuticals Inc (REGN) Regeneron Pharmaceuticals Inc (REGN)
Argenx NV ADR (ARGX) Argenx NV ADR (ARGX)
Revolution Medicines Inc (RVMD) Revolution Medicines Inc (RVMD)
Natera Inc (NTRA) Natera Inc (NTRA)
Alnylam Pharmaceuticals Inc (ALNY) Alnylam Pharmaceuticals Inc (ALNY)
BeOne Medicines AG DRC (ONC) BeOne Medicines AG DRC (ONC)
Biogen Inc (BIIB) Biogen Inc (BIIB)
Roivant Sciences Ltd (ROIV) Roivant Sciences Ltd (ROIV)
Moderna Inc (MRNA) Moderna Inc (MRNA)
BioNTech SE (BNTX) BioNTech SE (BNTX)
Insmed Inc (INSM) Insmed Inc (INSM)
Incyte Corporation (INCY) Incyte Corporation (INCY)
United Therapeutics Corporation (UTHR) United Therapeutics Corporation (UTHR)
Neurocrine Biosciences Inc (NBIX) Neurocrine Biosciences Inc (NBIX)
Genmab AS (GMAB) Genmab AS (GMAB)
BridgeBio Pharma Inc (BBIO) BridgeBio Pharma Inc (BBIO)
Ascendis Pharma AS (ASND) Ascendis Pharma AS (ASND)
Exelixis Inc (EXEL) Exelixis Inc (EXEL)
Madrigal Pharmaceuticals Inc (MDGL) Madrigal Pharmaceuticals Inc (MDGL)
Abivax SA ADR (ABVX) Abivax SA ADR (ABVX)
Biomarin Pharmaceutical Inc (BMRN) Biomarin Pharmaceutical Inc (BMRN)